Cytidine is a novel substrate for wild-type concentrative nucleoside transporter 2.
Nucleoside transporter (NT) plays key roles in the physiology of nucleosides and the pharmacology of its analogues in mammals. We previously cloned Na+/nucleoside cotransporter CNT2 from mouse M5076 ovarian sarcoma cells, the peptide encoded by it differing from that by the previously reported mouse CNT2 in five substitutions, and observed that the transporter can take up cytidine, like CNT1 and CNT3. In the present study, we examined which of the two aforementioned CNT2 is the normal one, and whether or not cytidine is transported via the previously reported CNT2. The peptide encoded by CNT2 derived from mouse intestine, liver, spleen, and ovary was identical to that previously reported. The uptake of [3H]cytidine, but not [3H]thymidine, by Cos-7 cells transfected with CNT2 cDNA obtained from mouse intestine was much greater than that by mock cells, as in the case of [3H]uridine, a typical substrate of NT. [3H]Cytidine and [3H]uridine were taken up via CNT2, in temperature-, extracellular Na+-, and substrate concentration-dependent manners. The uptake of [3H]cytidine and [3H]uridine mediated by CNT2 was significantly inhibited by the variety of nucleosides used in this study, except for thymidine, and inhibition of the [3H]uridine uptake by cytidine was competitive. The [3H]uridine uptake via CNT2 was significantly decreased by the addition of cytarabin or gemcitabine, antimetabolites of cytidine analogue. These results indicated that the previously reported mouse CNT2 is the wild-type one, and cytidine is transported mediated by the same recognition site on the CNT2 with uridine, and furthermore, cytidine analogues may be substrates for the transporter.
Nagai
Katsuhito
K
Department of Environmental Biochemistry, Kyoto Pharmaceutical University, Misasagi, Kyoto 607-8414, Japan. nagai@mb.kyoto-phu.ac.jp
Nagasawa
Kazuki
K
Koma
Mineto
M
Hotta
Ayumi
A
Fujimoto
Sadaki
S
D019943:Amino Acid Substitution; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D001692:Biological Transport / Q000187:drug effects; D019556:COS Cells; D002522:Chlorocebus aethiops; D003561:Cytarabine / Q000494:pharmacology; D003562:Cytidine / Q000493:pharmacokinetics* / Q000494:pharmacology; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005838:Genotype; D007700:Kinetics; D008297:Male; D026901:Membrane Transport Proteins / Q000235:genetics / Q000502:physiology*; D051379:Mice; D013936:Thymidine / Q000493:pharmacokinetics / Q000494:pharmacology; D014162:Transfection; D014316:Tritium; D014529:Uridine / Q000493:pharmacokinetics / Q000494:pharmacology; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D026901:Membrane Transport Proteins; C065171:cif nucleoside transporter; D003561:Cytarabine; D003841:Deoxycytidine; D014316:Tritium; D003562:Cytidine; D013936:Thymidine; D014529:Uridine; D000093542:Gemcitabine